Shares of Evotec SE (NASDAQ:EVO - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 352,319 shares changed hands during trading, an increase of 151% from the previous session's volume of 140,616 shares.The stock last traded at $3.68 and had previously closed at $3.27.
Evotec Price Performance
The firm's 50 day moving average is $3.68 and its 200-day moving average is $4.07. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.
Institutional Trading of Evotec
Several large investors have recently made changes to their positions in EVO. BNP Paribas Financial Markets bought a new position in shares of Evotec in the fourth quarter valued at approximately $27,000. CSS LLC IL bought a new position in Evotec in the 4th quarter worth $50,000. Bank of America Corp DE lifted its position in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC bought a new stake in Evotec during the fourth quarter valued at about $166,000. Finally, DCF Advisers LLC grew its position in shares of Evotec by 5.9% in the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the last quarter. Institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
